The LATAM Fabry disease market is estimated to be valued at USD 105.41 Mn in 2026 and is expected to reach USD 165.92 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 6.9% during the forecast period. The main factors that will drive growth in the market include increased awareness about rare genetic diseases, developments in diagnostics, increased use of ERTs, and novel treatment techniques. The role played by governments in controlling rare diseases and improving the healthcare infrastructure in Latin America has also been contributing towards growth in the market.
Consistent growth in the market is due to developments in enzyme replacement therapy, chaperone therapy, genetic testing, and personalized treatment solutions. Growth in the market is also supported by increased investment in research on rare diseases, improved newborn screening programs, and cooperation between pharmaceutical companies and healthcare organizations. Costly treatment, late diagnoses, poor awareness about the diseases, and lack of access to new treatment techniques in some countries are the key barriers to growth in the market.
The parenteral segment is expected to capture the highest market share, accounting for about 68% of the market in 2026. The high market share of the parenteral segment is owing to the increased use of IV-based enzyme replacement therapies, which have been established as the primary mode of treatment for Fabry disease. The development of biological drugs and improved accessibility of patients to IV-based treatments are expected to drive the growth of the segment during the forecast period.
Brazil is anticipated to lead the LATAM Fabry disease market over the forecast period on account of the presence of a large number of patients, an efficient healthcare system, an increase in the availability of treatment facilities, and supportive government programs related to the treatment of rare diseases.
Company Profiles
1. Novartis
Company Overview
- Headquarters: Basel, Switzerland
- Establishment Year: 1996
- Employee Strength: Approximately 75,000+ employees
- Leadership: Mr. Vas Narasimhan, Chief Executive Officer
- Core Services/Products: Rare disease therapies, gene therapies, specialty pharmaceuticals, cardiovascular medicines, oncology treatments, and advanced biologics.
- Geographic Presence: Operations in more than 140 countries worldwide.
SWOT Analysis
- Strengths
- Impressive portfolio of innovative drugs for rare conditions
- High investments on R&D activities
- Weaknesses
- Depends heavily on patented specialty drugs
- Has premium prices for novel drugs
- Opportunities
- Gene therapy expansion for rare genetic conditions
- Rare disease drug availability in Latin America
- Threats
- Expiration of some of the key patents
- Pricing and reimbursement issues
2. Teva Pharmaceutical Industries Ltd.
Company Overview
- Headquarters: Tel Aviv, Israel
- Establishment Year: 1901
- Employee Strength: Approximately 37,000+ employees
- Leadership: Mr. Richard Francis, President and Chief Executive Officer
- Core Services/Products: Generic medicines, specialty pharmaceuticals, biologics, rare disease treatments, and central nervous system therapies.
- Geographic Presence: Presence in over 60 countries.
SWOT Analysis
- Strengths
- Very competitive generics pharmaceutical industry
- Well-established production and distribution network
- Weaknesses
- Correlation with the generics pharmaceutical industry
- Being involved in lawsuits and experiencing financial difficulties
- Opportunities
- Specialty pharmaceutical products and orphan drugs
- Healthcare investment growth in Latin America
- Threats
- Competition in the generics pharmaceutical industry
- Legislation obstacles
3. Pfizer Inc.
Company Overview
- Headquarters: New York, U.S.
- Establishment Year: 1849
- Employee Strength: Approximately 88,000+ employees
- Leadership: Dr. Albert Bourla, Chairman and Chief Executive Officer
- Core Services/Products: Biopharmaceuticals, rare disease therapies, vaccines, oncology medicines, immunology products, and enzyme replacement therapies.
- Geographic Presence: Operations in more than 125 countries worldwide.
SWOT Analysis
- Strengths
- Well-established pharmaceutical company across the globe
- Well-equipped with research laboratories and diversified products
- Weaknesses
- Focused on premium-priced brands
- High risk of losing patents
- Opportunities
- Rising demand for treatments of rare diseases
- Precision medicine and biological drugs
- Threats
- Threat from increasing adoption of biosimilars
- Stringent global regulations
4. GlaxoSmithKline plc (GSK)
Company Overview
- Headquarters: London, U.K.
- Establishment Year: 2000
- Employee Strength: Approximately 70,000+ employees
- Leadership: Ms. Emma Walmsley, Chief Executive Officer
- Core Services/Products: Specialty medicines, vaccines, immunology therapies, rare disease treatments, and infectious disease medicines.
- Geographic Presence: Operations across more than 100 countries.
SWOT Analysis
- Strengths
- Highly proficient in specialty drugs and vaccines
- Adequate worldwide presence in terms of business
- Weaknesses
- Overreliance on existing pharmaceutical products
- High cost involved in research and development
- Opportunities
- Providing more therapies for rare diseases
- Better healthcare provision in developing countries
- Threats
- Severe competition from revolutionary biotech companies
- Pricing and reimbursement issues
5. Takeda Pharmaceuticals U.S.A., Inc.
Company Overview
- Headquarters: Lexington, Massachusetts, U.S. (Parent company: Takeda Pharmaceutical Company Limited, Japan)
- Establishment Year: 1781 (Parent company)
- Employee Strength: Approximately 50,000+ employees
- Leadership: Mr. Christophe Weber, President and Chief Executive Officer
- Core Services/Products: Rare disease therapies, plasma-derived treatments, gastrointestinal medicines, oncology therapies, and enzyme replacement therapies.
- Geographic Presence: Operations in more than 80 countries worldwide.
SWOT Analysis
- Strengths
- Successful leadership in rare diseases and plasma-based therapies
- Established expertise in research and manufacturing around the world
- Weaknesses
- Huge costs in operation and research
- Complex biologics manufacturing process
- Opportunities
- Greater demand for ERT
- Initiating rare disease programs in Latin America
- Threats
- Tardiness in approval from regulatory bodies
- Biotech new entrants
